Early data on long‐term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2‐year update from the open‐label extension of the NEURO‐TTR trial

BACKGROUND AND PURPOSE: Hereditary transthyretin (hATTR) amyloidosis causes progressive polyneuropathy resulting from transthyretin (TTR) amyloid deposition throughout the body, including the peripheral nerves. The efficacy and safety of inotersen, an antisense oligonucleotide inhibitor of TTR prote...

Descripción completa

Detalles Bibliográficos
Autores principales: Brannagan, T. H., Wang, A. K., Coelho, T., Waddington Cruz, M., Polydefkis, M. J., Dyck, P. J., Plante‐Bordeneuve, V., Berk, J. L., Barroso, F., Merlini, G., Conceição, I., Hughes, S. G., Kwoh, J., Jung, S. W., Guthrie, S., Pollock, M., Benson, M. D., Gertz, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Neuropathies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496583/
https://www.ncbi.nlm.nih.gov/pubmed/32343462
http://dx.doi.org/10.1111/ene.14285

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496583/
https://www.ncbi.nlm.nih.gov/pubmed/32343462
http://dx.doi.org/10.1111/ene.14285

Ejemplares similares